Drugs / HS-20004
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02750007 | Dec 2015 → Jan 2017 | type 2 diabetes mellitus | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02746315 | Oct 2014 → Feb 2015 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02746302 | Dec 2012 → Jan 2014 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03848793 | Mar 2019 → Jun 2020 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02746302 ↗ |
| Route | Subcutaneous | “Injected s.c. (under the skin)” NCT02746302 ↗ |